Maria Brotons (Spain)
Catalan Institute of Oncology Unit of Infections and Cancer - Information & InterventionsPresenter of 1 Presentation
PRE-VACCINE POPULATION-BASED ASSESSMENT OF HPV GENOTYPES IN CERVICAL CARCINOMA IN SITU AND INVASIVE CERVICAL CANCER IN CATALONIA, SPAIN (ID 135)
- Maria Brotons (Spain)
- Rafael Marcos-Gragera (Spain)
- Marià Carulla (Spain)
- Jaume Galceran (Spain)
- Beatriz Quiros (Spain)
- Omar Clavero (Spain)
- Luis Urbiztondo (Spain)
- Carmen Cabezas (Spain)
- Marleny Vergara (Spain)
- Ana Esteban (Spain)
- Yolanda Florencia (Spain)
- Vanessa Camon (Spain)
- Maria Alejo (Spain)
- Belen Lloveras (Spain)
- Eugeni López (Spain)
- Joan Josep Sirvent (Spain)
- Francesc Riu (Spain)
- Josepa Miró (Spain)
- Maria Jesús Muntané (Spain)
- Natalia Navas (Spain)
- Montse Llobet (Spain)
- Neus Guionnet (Spain)
- Antonio Urban (Spain)
- Lluís E. Pons (Spain)
- Marta Mestres (Spain)
- Julieta Landeyro (Spain)
- Francesc Tresserra (Spain)
- Mariona Novell (Spain)
- Maria José Martínez (Spain)
- Conxita Alomar (Spain)
- August Vidal (Spain)
- Joana Rabasseda (Spain)
- Enrique Lerma (Spain)
- Angel Carrasco (Spain)
- Angel Garcia (Spain)
- Carmen Martin (Spain)
- Josep Lluís Cases (Spain)
- Ramon Bordes (Spain)
- Miquel Ángel Pavón (Spain)
- Francesc Xavier Bosch José (Spain)
- Silvia De Sanjose (United States of America)
- Laia Bruni (Spain)
- Laia Alemany Vilches (Spain)
Abstract
Introduction
Catalonia, a region of 7.5 million inhabitants in northeast Spain, started in 2008 a school-based, single-cohort HPV vaccination programme targeting 11-year-old girls. We aimed to assess the pre-vaccine HPV-genotype distribution in cervical carcinoma in situ and adenocarcinoma in situ (CIS/AIS) and in invasive cervical cancer (ICC), to determine the potential impact of current HPV vaccines and establish the baseline for future impact evaluation.
Methods
In this population-based study, we identified through cancer registry databases all CIS/AIS and ICC cases diagnosed during 2003-2007 and 1998-2007, respectively, in Tarragona and Girona provinces. Pathology laboratories provided archival formalin-fixed paraffin-embedded specimens. SPF-10PCR/DEIA/LiPA25 system was used for HPV detection and genotyping. Negative cases were assessed for DNA quality. We estimated the HPV prevalence and relative contribution (RC) of the genotypes included in the current HPV vaccines.
Results
During the study period, 837 histologically-confirmed CIS/AIS and 556 ICC cases were identified. A total of 664 CIS/AIS cases and 380 ICC cases with valid HPV DNA results were obtained. HPV DNA was detected in 95.5% of CIS/AIS and 76.8% of ICC. Invasive adenocarcinoma and older ages were more prone to be HPV negative. RC of HPV16/18 was 61.1% and 75.6% in CIS/AIS and ICC, respectively, and RC of HPV 6/11/16/18/31/33/45/52/58 was 90.9% and 92.8%, respectively. Estimates will be presented by age, histology and cancer stage.
Conclusions
We obtained the baseline data for monitoring future trends.The HPV vaccination programme in Catalonia will substantially reduce the incidence of CIS/AIS and ICC. Surveillance through population-based cancer-registry genotyping of cancer/CIS cases is challenging and costly but will provide with the highest level of evidence on the impact of HPV vaccination on invasive cancer. Catalonia may be used as HPV surveillance site in a potential international network of selected cancer registries to monitor type-specific trends by age, histology and stage.